16,400 Shares in Celldex Therapeutics, Inc. $CLDX Purchased by SBI Okasan Asset Management Co.Ltd.

SBI Okasan Asset Management Co.Ltd. bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 16,400 shares of the biopharmaceutical company’s stock, valued at approximately $427,000.

Several other institutional investors have also recently made changes to their positions in CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 680 shares in the last quarter. Millennium Management LLC grew its position in shares of Celldex Therapeutics by 327.3% during the first quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after purchasing an additional 306,330 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Celldex Therapeutics by 12.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after purchasing an additional 14,979 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new stake in shares of Celldex Therapeutics during the second quarter worth about $347,000.

Celldex Therapeutics Trading Down 0.9%

Shares of CLDX opened at $31.43 on Friday. Celldex Therapeutics, Inc. has a twelve month low of $18.55 and a twelve month high of $35.79. The company has a market cap of $2.47 billion, a P/E ratio of -7.38 and a beta of 0.98. The company’s fifty day simple moving average is $32.16 and its 200-day simple moving average is $28.49.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.80 million. Analysts predict that Celldex Therapeutics, Inc. will post -4.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on CLDX. Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Barclays increased their target price on Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. The Goldman Sachs Group raised their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Monday, March 2nd. Stifel Nicolaus restated a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $49.78.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.